{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T08:37:00Z","timestamp":1792917420894,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.celrep.2026.118196","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:18:13Z","timestamp":1792675093000},"page":"118196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"45","author":[{"given":"Limu","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haokang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Po","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2104-6828","authenticated-orcid":false,"given":"Liye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.118196_bib1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.118196_bib2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118196_bib3","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"Vander Velde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.celrep.2026.118196_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","article-title":"Global liver disease burdens and research trends: Analysis from a Chinese perspective","volume":"71","author":"Xiao","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2026.118196_bib6","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.celrep.2026.118196_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41392-024-02104-8","article-title":"Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.celrep.2026.118196_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41575-020-0314-8","article-title":"Modern therapeutic approaches for the treatment of malignant liver tumours","volume":"17","author":"Petrowsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2026.118196_bib9","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.118196_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.118196_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.118196_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118196_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107082","article-title":"Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway","volume":"200","author":"Huang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.celrep.2026.118196_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107434","article-title":"Targeting PPP1R15B and ATF4 axis in hepatocellular carcinoma: A novel strategy for overcoming lenvatinib-tolerant persister cells through GPX4-mediated ferroptosis induction","volume":"218","author":"Chen","year":"2026","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.celrep.2026.118196_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","article-title":"Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma","volume":"19","author":"Pan","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.celrep.2026.118196_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-Methyladenosine\u2013Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells\u2019 Properties and Lenvatinib Resistance Through WNT\/\u03b2-Catenin and Hippo Signaling Pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.118196_bib17","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41388-024-03153-7","article-title":"GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma","volume":"43","author":"Xie","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.118196_bib18","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","article-title":"Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma","volume":"14","author":"Leung","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib19","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/hep4.1928","article-title":"Integrin subunit beta 8 contributes to lenvatinib resistance in HCC","volume":"6","author":"Hou","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-024-01963-5","article-title":"The p-MYH9\/USP22\/HIF-1\u03b1 axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma","volume":"9","author":"Shan","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.celrep.2026.118196_bib21","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3\u2013ABCB1 Signaling in Hepatocellular Carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.118196_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.118196_bib23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.118196_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/2159-8290.CD-12-0400","article-title":"Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation","volume":"2","author":"Trusolino","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.118196_bib25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118196_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1042\/BJ20071505","article-title":"EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate","volume":"410","author":"Stern","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.celrep.2026.118196_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm3048","article-title":"Feedback regulation of EGFR signalling: decision making by early and delayed loops","volume":"12","author":"Avraham","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2026.118196_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.celrep.2026.118196_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/cas.12225","article-title":"Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation","volume":"104","author":"Sato","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.celrep.2026.118196_bib30","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1038\/onc.2013.442","article-title":"Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling","volume":"33","author":"Kamekura","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.118196_bib31","doi-asserted-by":"crossref","first-page":"vii109","DOI":"10.1093\/annonc\/mdl962","article-title":"Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy","volume":"17","author":"Ciardiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2026.118196_bib32","author":"Robert"},{"key":"10.1016\/j.celrep.2026.118196_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117032","article-title":"Molecular Dissection of the AHR-AREG driven EGFR-ERK1\/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma","volume":"239","author":"Hu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.celrep.2026.118196_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Blivet-Van Eggelpo\u00ebl","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2026.118196_bib35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-025-56537-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-024-02085-8","article-title":"Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.celrep.2026.118196_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216122","article-title":"METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.celrep.2026.118196_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","article-title":"METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.118196_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41392-026-02649-w","article-title":"Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma","volume":"11","author":"Xu","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.celrep.2026.118196_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.118196_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.118196_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13027","article-title":"Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression","volume":"18","author":"Xu","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.celrep.2026.118196_bib43","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues","volume":"13","author":"Saul","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib44","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41467-018-04010-4","article-title":"The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.118196_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","article-title":"Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair","volume":"42","author":"Zaiss","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.118196_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/genetics\/iyaa021","article-title":"Pan cancer patterns of allelic imbalance from chromosomal alterations in 33 tumor types","volume":"217","author":"Sivakumar","year":"2021","journal-title":"Genetics"},{"key":"10.1016\/j.celrep.2026.118196_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41586-023-06102-8","article-title":"Deterministic evolution and stringent selection during preneoplasia","volume":"618","author":"Karlsson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118196_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.118196_bib49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41585-022-00659-1","article-title":"PBRM1, SETD2 and BAP1 \u2014 the trinity of 3p in clear cell renal cell carcinoma","volume":"20","author":"Walton","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.celrep.2026.118196_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.2549","article-title":"Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma","volume":"36","author":"Hsieh","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.118196_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-065X.2012.01101.x","article-title":"DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out","volume":"246","author":"McCool","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.celrep.2026.118196_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-kappaB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.celrep.2026.118196_bib53","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.118196_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","article-title":"Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.118196_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112546","article-title":"Modeling human ectopic pregnancies with trophoblast and vascular organoids","volume":"42","author":"Zhao","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.118196_bib56","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41587-023-01863-z","article-title":"De novo detection of somatic mutations in high-throughput single-cell profiling data sets","volume":"42","author":"Muyas","year":"2024","journal-title":"Nat. Biotechnol."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726012751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726012751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T08:12:43Z","timestamp":1792915963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726012751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2211124726012751"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118196","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.118196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118196"}}